{"id":689612,"date":"2022-09-28T07:04:30","date_gmt":"2022-09-28T11:04:30","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/nuvasive-launches-reline-cervical-for-posterior-cervical-fusion-as-part-of-the-c360-portfolio\/"},"modified":"2022-09-28T07:04:30","modified_gmt":"2022-09-28T11:04:30","slug":"nuvasive-launches-reline-cervical-for-posterior-cervical-fusion-as-part-of-the-c360-portfolio","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/nuvasive-launches-reline-cervical-for-posterior-cervical-fusion-as-part-of-the-c360-portfolio\/","title":{"rendered":"NuVasive Launches Reline Cervical for Posterior Cervical Fusion as Part of the C360 Portfolio"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n The cervical solution marks the completion of the NuVasive Reline fixation portfolio for complex deformity from occiput to sacrum<\/i>\n <\/p>\n

\n
\n SAN DIEGO<\/span>
\n <\/span>, Sept. 28, 2022<\/span><\/span> \/PRNewswire\/ — NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced today the commercial launch of Reline\u00ae<\/sup> Cervical, a new fixation system for posterior cervical fusion (PCF), in targeted regions.<\/p>\n

\n

\n
\n \"NuVasive
\n <\/a>\n <\/p>\n<\/p><\/div>\n

“Reline Cervical completes the foundational three strategic pillars of C360<\/a>\u2122\u2014anterior cervical decompression and fusion, cervical total disc replacement, and now PCF. This launch is a significant step forward for our fixation portfolio and furthers our goal of becoming the market leader in complex deformity while extending our position with the industry’s leading cervical portfolio,” said\u00a0Ryan Donahoe, chief technology officer at\u00a0NuVasive. “We have leveraged our expertise with the proven Reline system, combined with Pulse\u00ae<\/sup>, to deliver our best PCF solution. The key advancements in this procedural technology fuel continued growth and differentiation in the cervical spine segment.”<\/p>\n

As cervical spine procedures comprise an approximately\u00a0$2.6 billion\u00a0subsegment of the global spine market, the introduction of Reline Cervical will allow the Company’s C360 portfolio to take even more share. Surgeons can address complex PCF surgeries within one comprehensive fixation portfolio, as well as utilize the enabling technologies within Pulse. The compatibility of Reline Cervical with Pulse gives surgeons the benefits of navigation, imaging enhancement, intraoperative neuromonitoring, iGA\u00ae<\/sup>, and patient-specific rod bending.<\/p>\n

“The Reline Cervical design is best-in-class. I’m impressed by the screw range, great connector options, and the full junctional offering, helping me address the varying complex deformity cases I see in my practice,” said Steven\u00a0Ludwig, M.D., orthopedic spine surgeon at the University of Maryland.\u00a0“Having the benefits of the thoracolumbar Reline system now in the cervical spine gives me confidence that I’m giving my patients the best solution.”<\/p>\n

The expansion of the C360 portfolio further supports a comprehensive anterior and posterior offering of instrumentation, implants, biologic materials, and enabling technologies for any cervical procedure.<\/p>\n

NuVasive\u00a0will feature its C360 portfolio at these upcoming 2022 events:<\/p>\n